马里波萨-2:治疗比疾病更糟糕吗?
Alexandria T M Lee1, Sai-Hong Ignatius Ou2
1University of California Irvine School of Medicine, Department of Medicine, Orange, CA 92868, USA.
Med (New York, N.Y.)
|February 10, 2024
概括
在EGFR+非小细胞肺癌 (NSCLC) 中,在一线奥西默蒂尼布,新型四重 (拉泽蒂尼布,阿米万塔马布,化疗) 和三重 (阿米万塔马布,化疗) 疗法后,改善了无进展的生存率. 然而,较高的不良事件可能会限制治疗适应.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 经EGFR突变的非小细胞肺癌 (NSCLC) 仍然是第一线 osimertinib 治疗后的一个重大挑战.
- 研究新的组合疗法对于克服耐药性和改善患者治疗结果至关重要.
研究的目的:
- 为了评估"四方" (拉泽提尼布+阿米万塔马布+化疗) 和"三重" (阿米万塔马布+化疗) 方案的疗效和安全性,与单独的化疗相比,EGFR+NSCLC患者在一线 osimertinib 治疗后进展.
- 评估不良事件对这些新疗法治疗适应性的影响.
主要方法:
- 一项研究比较了EGFR+NSCLC患者的四重 (拉泽蒂尼布,阿米万塔马布,化疗) 和三重 (阿米万塔马布,化疗) 疗法与化疗 (CP) 的治疗方案.
- 分析无进展生存 (PFS) 和需要剂量修改的不良事件 (AE) 的发生率.
主要成果:
- 与单独的化疗相比,四倍和三倍疗法都显示出改善了中位数无进展生存率.
- 在三倍和四倍组中观察到需要剂量修改的不良事件的高发病率.
结论:
- 新的四倍和三倍疗法在改善EGFR+NSCLC患者的PFS方面显示出有前途.
- 耐受性和因不良事件而改变剂量的可能性需要仔细考虑这些先进治疗策略的临床适应.
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Pulmonary Tuberculosis II
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...


